Postoperative Pain
Conditions
Keywords
preemptive analgesia, lumbar fusion, Parecoxib, Ketorolac
Brief summary
The purpose of this study is to evaluate the efficacy of Parecoxib and Ketorolac as a preemptive analgesia in patients undergoing lumbar spinal fusion.
Detailed description
A prospective, double-blinded randomized control trial. Randomly allocated patient undergoing posterior lumbar spinal fusion into 3 groups (n=32) to receive Parecoxib, Ketorolac and Placebo around 30 minutes prior to incised skin. Efficacy was assessed by visual analog scale score (0-10), total opioid consumption, complication and bleeding also recorded.
Interventions
DRUGParecoxib
Parecoxib 40 mg intravenous
DRUGKetorolac
Ketorolac 30 mg intravenous
Sponsors
Prince of Songkla University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients undergoing lumbar spinal fusion for one to three levels * ASA class I or II
Exclusion criteria
* History of allergy to Sulfa group * History of allergy to OPOID or NSAIDs * Contraindicate to NSAIDs use * History of coagulopathy or platelet disfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | Postoperative time up to 24 hours | recorded as Verbal Numerical Rating Scare 0-10 |
Secondary
| Measure | Time frame |
|---|---|
| Total amount of opioid consumption postoperatively | Postoperative 24 hours |
Other
| Measure | Time frame |
|---|---|
| Amount of drain output and Other Adverse effect | 7 days postoperatively |
Countries
Thailand
Outcome results
None listed